Reata Pharmaceuticals, Inc. (RETA) Financial Statements (2024 and earlier)

Company Profile

Business Address 5320 LEGACY DRIVE
PLANO, TX 75024
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments387,514590,258818,150664,324337,790129,780
Cash and cash equivalents42,312590,258818,150664,324337,790129,780
Short-term investments345,202     
Receivables  22,228   
Inventory, net of allowances, customer advances and progress billings      
Inventory      
Deferred costs      404
Other undisclosed current assets10,2566,2176,9604,9524,4832,925
Total current assets:397,770596,475847,338669,276342,273133,109
Noncurrent Assets
Inventory, Noncurrent      
Operating lease, right-of-use asset105,258126,777  
Property, plant and equipment11,17911,6044,9122,9961,445718
Other noncurrent assets2841605,34810,1481,4901,510
Total noncurrent assets:116,721138,54110,26013,1442,9352,228
TOTAL ASSETS:514,491735,016857,598682,420345,208135,337
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32,54227,75418,81325,68219,88914,694
Accounts payable18,70613,5054,7901,9084,4732,067
Accrued liabilities13,83614,24914,02323,77415,41612,627
Deferred revenue  1,6484,6884,701
Debt    3,156 1,229
Other liabilities24,26721,45022,26411,6314,6963,511
Deferred revenue and credits28,183
Contract with customer, liability31,335
Other undisclosed current liabilities2,1513,14273,437146,844  
Total current liabilities:58,96053,994119,202192,01455,92047,617
Noncurrent Liabilities
Long-term debt and lease obligation  132,8912,482161,999  
Long-term debt, excluding current maturities    155,017  
Liabilities, other than long-term debt117,313 5,51111,670194,910216,308
Deferred revenue and credits216,255
Deferred revenue    4,688
Contract with customer, liability194,386
Other liabilities   5,5116,98252453
Operating lease, liability117,313132,8912,4826,982
Other undisclosed noncurrent liabilities403,913229,251312,97259,88079,21918,385
Total noncurrent liabilities:521,226495,033320,965233,549274,129234,693
Total liabilities:580,186549,027440,167425,563330,049282,310
Equity
Equity, attributable to parent, including:(65,695)185,989417,431256,85715,159(146,973)
Additional paid in capital1,501,8001,441,5841,375,640967,317435,452190,145
Accumulated deficit(1,567,532)(1,255,631)(958,245)(710,493)(420,323)(337,143)
Stockholders' equity note, subscriptions receivable      (2)
Other undisclosed equity, attributable to parent373636333027
Total equity:(65,695)185,989417,431256,85715,159(146,973)
TOTAL LIABILITIES AND EQUITY:514,491735,016857,598682,420345,208135,337

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues2,21611,4909,01926,51753,58948,058
Revenue, net48,058
Gross profit:2,21611,4909,01926,51753,58948,058
Operating expenses(280,250)(256,198)(235,344)(311,737)(130,467)(94,970)
Operating loss:(278,034)(244,708)(226,325)(285,220)(76,878)(46,912)
Nonoperating income (expense)(33,892)(53,128)(43,914)(4,942)(3,642)(756)
Investment income, nonoperating5,9901772,7696,2483,541701
Other nonoperating income (expense)1,889(54)(9,904)7 (3)
Interest and debt expense (6,563)(11,183)(11,197)(1,007)(1,454)
Loss from continuing operations before equity method investments, income taxes:(311,926)(304,399)(281,422)(301,359)(81,527)(49,122)
Other undisclosed income from continuing operations before income taxes 6,56311,18311,1971,0071,454
Loss from continuing operations before income taxes:(311,926)(297,836)(270,239)(290,162)(80,520)(47,668)
Income tax expense (benefit)2545022,487(8)(26)(3)
Loss from continuing operations:(311,901)(297,386)(247,752)(290,170)(80,546)(47,671)
Loss before gain (loss) on sale of properties:(297,386)(247,752)(290,170)(80,546)(47,671)
Net loss available to common stockholders, diluted:(311,901)(297,386)(247,752)(290,170)(80,546)(47,671)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(311,901)(297,386)(247,752)(290,170)(80,546)(47,671)
Comprehensive loss, net of tax, attributable to parent:(311,901)(297,386)(247,752)(290,170)(80,546)(47,671)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: